BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across ...

决奈达隆的商品名为Multaq ，是赛诺菲安万特公司开发的III 类抗心律失常药物。该药物于 2009 年 7 月获美国食品药品管理局 (FDA)批准。除了用于治疗心律失常外，它还被推荐作为胺碘酮的替代品，用于治疗心房颤动和心房扑动，适用于心脏已恢复正常节律或接受药物治疗或电击治疗，即直流电复律 (DCCV) 以维持正常节律的患者。

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition ...

OGSIVEO是一种γ分泌酶抑制剂，适用于需要全身治疗的进行性硬纤维瘤成年患者 。 【OGSIVEO剂量和用法】 • 建议剂量为150mg，每日两次口服，直到疾病进展或不可接受的毒性。 • 有关因不良反应导致的剂量调整，请参见完整的处方信息。 无。 ...

Avoid coadministration of GAVRETO with strong or moderate CYP3A inhibitors, P-gp inhibitors, or combined P-gp and strong or moderate CYP3A inhibitors. If coadministration cannot be avoided ...

CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare ...

CYP3A Inhibitors: When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA ...